BackNervGen Pharma Common stock Overview

NervGen Pharma Common stock Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$8.09M
198.35% YoY

As of Jun 30, 2026

Annual R&D Expenses (TTM)

$24.01M
62.11% YoY

Trailing 12 months ending Jun 30, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

NervGen Pharma Common stock (NGEN) FAQ

Stockcircle tracks research & development for NervGen Pharma Common stock (NGEN), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for NervGen Pharma Common stock's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main NGEN overview so you can move from this figure to the surrounding analysis quickly.